Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years-Reference-Cited by-同舟云学术

Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years

Published:2020-05-13 Issue:1 Volume:15 Page:2-13
ISSN:1574-8928
Container-title:Recent Patents on Anti-Cancer Drug Discovery
language:en
Short-container-title:PRA

Author:

Tao Hongyu¹,Zuo Ling²,Xu Huanli¹,Li Cong¹,Qiao Gan²,Guo Mingyue²,Lin Xiukun²

Affiliation:

1. Department of Pharmacology, School of Basic Medicine, Capital Medical University, Beijing 100069, China

2. Department of Pharmacology, School of Pharmacy, Southwest Medical University, Sichuan 646000, China

Abstract

Background:In recent years, many novel alkaloids with anticancer activity have been found in China, and some of them are promising for developing as anticancer agents.Objective:This review aims to provide a comprehensive overview of the information about alkaloid anticancer agents disclosed in Chinese patents, and discusses their potential to be developed as anticancer drugs used clinically.Methods:Anticancer alkaloids disclosed in Chinese patents in recent 5 years were presented according to their mode of actions. Their study results published on PubMed, and SciDirect databases were presented.Results:More than one hundred anticancer alkaloids were disclosed in Chinese patents and their mode of action referred to arresting cell cycle, inhibiting protein kinases, affecting DNA synthesis and p53 expression, etc.Conclusion:Many newly found alkaloids displayed potent anticancer activity both in vitro and in vivo, and some of the anticancer alkaloids acted as protein kinase inhibitors or CDK inhibitors possess the potential for developing as novel anticancer agents.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

Reference136 articles.

1. Schläger S.; Dräger B.; Exploiting plant alkaloids. Curr Opin Biotechnol 2016,37,155-164

2. Yang C.H.; Horwitz S.B.; Taxol: The first microtubule stabilizing agent. Int J Mol Sci 2017,18(8),1733

3. Shah N.N.; Merchant M.S.; Cole D.E.; Jayaprakash N.; Bernstein D.; Delbrook C.; Richards K.; Widemann B.C.; Wayne A.S.; Vincristine Sulfate Liposomes Injection (VSLI, Marqibo(R)): Results from a Phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias. Pediatr Blood Cancer 2016,63(6),997-1005

4. Martino E.; Della Volpe S.; Terribile E.; Benetti E.; Sakaj M.; Centamore A.; Sala A.; Collina S.; The long story of camptothecin: From traditional medicine to drugs. Bioorg Med Chem Lett 2017,27(4),701-707

5. Whittaker S.R.; Mallinger A.; Workman P.; Clarke P.A.; Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther 2017,173,83-105

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salinity Stress Acclimation Strategies in Chlamydomonas sp. Revealed by Physiological, Morphological and Transcriptomic Approaches;Marine Drugs;2024-07-29

2. A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges;Drug Development Research;2024-04-29

3. Piperlongumine and its derivatives against cancer: A recent update and future prospective;Archiv der Pharmazie;2024-04-09

4. Alkaloids from African plants as pharmaceuticals to combat cancer drug resistance;Advances in Botanical Research;2024

5. The Role of Propolis as a Natural Product with Potential Gastric Cancer Treatment Properties: A Systematic Review;Foods;2023-01-16